PCOS Renamed PMOS in Landmark Consensus Published in The Lancet

A landmark international consensus study published in The Lancet has formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), a change that its authors argue will fundamentally reorient how clinicians diagnose, classify, and treat one of the most prevalent endocrine conditions in reproductive-age individuals worldwide.¹

The renaming carries direct clinical implications. The old nomenclature has anchored the condition in gynecological and reproductive framing, long thought to obscure its well-documented metabolic, cardiovascular, dermatological, and psychological dimensions. The shift to PMOS is intended to correct that structural mischaracterization at the level of disease classification, medical education, and international diagnostic coding systems.

A Name That No Longer Reflects the Science

"Renaming this condition is more than semantics; it's about finally recognizing the full reality of what patients experience," Melanie Cree, MD, PhD, a pediatric endocrinologist at the University of Colorado Anschutz Medical Campus and one of two US-based pediatric endocrinologists involved in the international consensus effort, said in a press release. "For too long, the narrow definition of PCOS has overlooked its metabolic and hormonal complexity, leaving many patients undiagnosed or misunderstood."

According to the consensus publication, the term "polycystic ovary syndrome" has been recognized for decades as both inaccurate and clinically limiting. A central problem: a substantial proportion of patients diagnosed with the condition do not have ovarian cysts. The polycystic descriptor, therefore, has historically misdirected clinical attention and public understanding alike.

The new designation—Polyendocrine Metabolic Ovarian Syndrome—was structured to address three specific deficiencies in the prior name: it acknowledges the condition's hormonal complexity across multiple endocrine axes (polyendocrine), incorporates its metabolic and cardiometabolic burden, and retains reference to ovarian involvement without reducing the condition to a reproductive disorder.

Clinical Burden and the Cost of Misclassification

PMOS affects more than 170 million individuals worldwide, according to the consensus authors.¹ Despite this prevalence, the condition has historically been associated with diagnostic delays, fragmented multidisciplinary care, and significant psychosocial stigma—consequences that researchers and patient advocates have attributed, in part, to terminology that emphasized fertility over systemic health.

Cardiometabolic risk is among the most clinically underappreciated dimensions of the condition. Insulin resistance, dyslipidemia, and elevated risk for type 2 diabetes and cardiovascular disease are well-documented features of what was previously classified as PCOS, yet these risks have often received secondary attention in clinical practice relative to menstrual irregularity and infertility concerns.²

Mechanism, Scope, and the Renaming Rationale

PMOS is characterized by hyperandrogenism, ovulatory dysfunction, and metabolic dysregulation involving insulin signaling pathways. Its pathophysiology spans the hypothalamic-pituitary-ovarian axis, adrenal function, and peripheral insulin sensitivity—an inherently polyendocrine profile that the prior name failed to capture.³

The consensus process incorporated input from thousands of clinicians and patients across multiple countries, according to the authors. Alongside the renaming, implementation is expected to include updates to clinical practice guidelines, international disease classification systems such as the ICD, and medical school curricula.

"Language matters in medicine," noted Cree. "The previous name often led to misconceptions and stigma, particularly around fertility. This change helps shift the conversation toward overall health rather than a single aspect of the condition."

Interpretive Caution

While the renaming represents a meaningful conceptual advance, its practical impact on clinical outcomes will depend on how consistently the new terminology is adopted across primary care, endocrinology, gynecology, and cardiology. Renaming alone does not resolve existing gaps in screening protocols or access to multidisciplinary care. Longitudinal data will be required to assess whether reclassification translates into measurable improvements in time-to-diagnosis or cardiometabolic outcomes.

"What makes this effort especially powerful is that it reflects the voices of thousands of patients and clinicians from around the world," said Cree. "This renaming sets the foundation for meaningful change—from medical education to clinical guidelines to public awareness, and ultimately, better outcomes for patient care."

References

1. Cree M et al. Polyendocrine Metabolic Ovarian Syndrome: international consensus renaming of polycystic ovary syndrome. Lancet. Published May 12, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
2. Dokras A, Saini S, Gibson-Helm M, et al. Gaps in cardiovascular risk factor assessment and management in women with polycystic ovary syndrome. Gynecol Endocrinol. 2017;33(7):509-513.
3. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-284.
4. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618.